Beiying Ding

6.5k total citations
52 papers, 2.0k citations indexed

About

Beiying Ding is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Beiying Ding has authored 52 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 14 papers in Surgery and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Beiying Ding's work include Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Neutropenia and Cancer Infections (10 papers). Beiying Ding is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Neutropenia and Cancer Infections (10 papers). Beiying Ding collaborates with scholars based in United States, Spain and France. Beiying Ding's co-authors include Paul D. Miller, Michael A. Bolognese, Javier San Martín, E. Michael Lewiecki, Michael R. McClung, Yu Liu, Matthew Austin, Rachel B. Wagman, Robert Gentleman and Yohann Loriot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Beiying Ding

49 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beiying Ding United States	21	1.3k	739	717	287	272	52	2.0k
Carla A. Wijbrandts Netherlands	30	384 0.3×	40 0.1×	443 0.6×	619 2.2×	117 0.4×	47	2.9k
F. Calabresi Italy	21	910 0.7×	37 0.1×	285 0.4×	133 0.5×	378 1.4×	52	1.5k
Hou‐Qun Ying China	23	929 0.7×	47 0.1×	692 1.0×	67 0.2×	307 1.1×	62	2.0k
Tim Shaw United States	9	272 0.2×	21 0.0×	199 0.3×	640 2.2×	93 0.3×	16	2.5k
Argiris Symeonidis Greece	25	616 0.5×	44 0.1×	847 1.2×	39 0.1×	80 0.3×	179	2.4k
Salvatore Mazzeo Italy	23	354 0.3×	13 0.0×	325 0.5×	214 0.7×	835 3.1×	48	2.2k
Luca Molinaro Italy	21	240 0.2×	59 0.1×	281 0.4×	220 0.8×	236 0.9×	66	1.3k
Alfonso Corrales Spain	25	126 0.1×	27 0.0×	336 0.5×	93 0.3×	221 0.8×	90	1.9k
Thi Dan Linh Nguyen‐Kim Switzerland	21	339 0.3×	18 0.0×	180 0.3×	463 1.6×	320 1.2×	73	1.6k
Mercedes Alperí Spain	25	183 0.1×	50 0.1×	245 0.3×	80 0.3×	84 0.3×	91	1.3k

Countries citing papers authored by Beiying Ding

Since Specialization

Citations

This map shows the geographic impact of Beiying Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beiying Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beiying Ding more than expected).

Fields of papers citing papers by Beiying Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beiying Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beiying Ding. The network helps show where Beiying Ding may publish in the future.

Co-authorship network of co-authors of Beiying Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Beiying Ding. A scholar is included among the top collaborators of Beiying Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beiying Ding. Beiying Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39. 1 indexed citations

Felip, Enriqueta, Eric Vallières, C.Z. Zhou, et al.. (2021). LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1319–S1319. 8 indexed citations

Toh, Han Chong, Philippe Merle, Kaoru Tsuchiya, et al.. (2020). O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150. Annals of Oncology. 31. 234–234. 12 indexed citations

Bamias, Aristotelis, Maria De Santis, José Ángel Arranz, et al.. (2020). 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 31. S551–S552. 6 indexed citations

Liu, Stephen V., Aaron S. Mansfield, Aleksandra Szczęsna, et al.. (2018). PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. Journal of Thoracic Oncology. 13(10). S185–S186. 5 indexed citations

Sadda, Srinivas R., Lisa Tuomi, Beiying Ding, Anne E. Fung, & J. Jill Hopkins. (2018). Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 125(6). 878–886. 115 indexed citations

Balar, Arjun Vasant, Robert Dreicer, Yohann Loriot, et al.. (2018). Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.. Journal of Clinical Oncology. 36(15_suppl). 4523–4523. 28 indexed citations

Necchi, Andrea, Richard W. Joseph, Yohann Loriot, et al.. (2017). Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Annals of Oncology. 28(12). 3044–3050. 214 indexed citations

Lancaster, Lisa, Lake Morrison, Alexander Auais, et al.. (2017). Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulmonary Therapy. 3(2). 317–325. 14 indexed citations

10.

Pieramici, Dante J., et al.. (2016). Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE. Ophthalmology. 123(6). 1345–1350. 46 indexed citations

11.

Holz, Frank G., Lisa Tuomi, Beiying Ding, & J. Jill Hopkins. (2015). Development of atrophy in neovascular AMD treated with ranibizumab in the HARBOR study. Investigative Ophthalmology & Visual Science. 56(7). 890–890. 5 indexed citations

12.

Regillo, Carl D., Brandon Busbee, Allen C. Ho, Beiying Ding, & Zdenka Hašková. (2015). Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. American Journal of Ophthalmology. 160(5). 1014–1023.e2. 59 indexed citations

13.

Goss, Paul E., Carlos H. Barrios, Arlene Chan, et al.. (2013). Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. Journal of Clinical Oncology. 31(15_suppl). TPS662–TPS662. 6 indexed citations

14.

McClung, Michael R., E. Michael Lewiecki, Michelle Geller, et al.. (2012). Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporosis International. 24(1). 227–235. 84 indexed citations

15.

Miller, Paul D., Rachel B. Wagman, Munro Peacock, et al.. (2010). Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 96(2). 394–402. 104 indexed citations

16.

Beck, Thomas, E. Michael Lewiecki, Paul D. Miller, et al.. (2008). Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate. Journal of Clinical Densitometry. 11(3). 351–359. 42 indexed citations

17.

Miller, Paul D., Michael A. Bolognese, E. Michael Lewiecki, et al.. (2008). Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 43(2). 222–229. 427 indexed citations

18.

Mirtsching, B., et al.. (2007). Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy. 5. 38–39. 1 indexed citations

19.

Noga, Stephen J., J. K. Choksi, Beiying Ding, Lyndah Dreiling, & Howard Ozer. (2007). Low Incidence of Neutropenic Events in Patients with Lymphoma Receiving First-Cycle Pegfilgrastim with Chemotherapy: Results from a Prospective Community-Based Study. Clinical Lymphoma & Myeloma. 7(6). 413–420. 8 indexed citations

20.

Morrison, Vicki A., Mitchell D. Wong, Dawn L. Hershman, et al.. (2007). Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices. Journal of Managed Care Pharmacy. 13(4). 337–348. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact